Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers.

Gurung M. et al, (2021), Pediatr Infect Dis J

Should we be vaccinating children against COVID-19 in high-income countries?

Li G. et al, (2021), Expert Rev Vaccines, 1 - 4

CoronaVac: more data for regulators and policy makers.

Ramasamy MN. and Jessop LJ., (2021), Lancet, 398, 186 - 188

Comparison of the Immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong: An Observational Cohort Study

Mok CKP. et al, (2021), SSRN Electronic Journal

The role of interspecies recombination in the evolution of antibiotic-resistant pneumococci.

D'Aeth JC. et al, (2021), Elife, 10

T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.

Swanson PA. et al, (2021)

"Should children be offered covid-19 vaccination?" No

Wilkinson D. et al, (2021), BMJ: British Medical Journal

Symptom study app provides real-world data on COVID-19 vaccines.

Drury RE. and O'Connor D., (2021), Lancet Infect Dis, 21, 890 - 891

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

Liu X. et al, (2021), SSRN Electronic Journal

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Flaxman A. et al, (2021)

A Salmonella Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination.

Jones E. et al, (2021), Microorganisms, 9

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial

Pollock KM. et al, (2021), SSRN Electronic Journal

Molecular epidemiology and antimicrobial resistance phenotype of paediatric bloodstream infections caused by Gram-negative bacteria in Oxfordshire, UK

Lipworth S. et al, (2021)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial

EWER K. et al, (2021), Lancet HIV

Divergent trajectories of antiviral memory after SARS-Cov-2 infection

Tomic* A. et al, (2021)

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply.

Voysey M. and Pollard AJ., (2021), Lancet, 397

SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties.

Oliu-Barton M. et al, (2021), Lancet, 397, 2234 - 2236

Charting mandatory childhood vaccination policies worldwide.

Vanderslott S. and Marks T., (2021), Vaccine

Injection fears and COVID-19 vaccine hesitancy

FREEMAN D., (2021), Psychological Medicine

Corrigendum to 'Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom'.

Versteegen P. et al, (2021), EBioMedicine, 68

Load More

«
...
32
33
34
35
36
37
38
...
»

Include forthcoming?